Introduction
============

Acute myeloid leukemia (AML) is a very heterogeneous disease, which is characterized by the occurrence of abnormal blasts of different maturation stages in the bone marrow (BM), perturbing normal hematopoiesis. Current standard for the induction treatment of AML is a combination of cytarabine with anthracyclines, resulting in a complete remission rate of 60--80% however, 50--70% of them experience a relapse.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ Recurrence of the disease is attributed to leukemia-initiating cells, also referred to as leukemic stem cells (LSCs), which are thought to be spared from chemotherapy and capable of reinitiating the disease.^[@bib5]^ Thus, successful novel therapeutic strategies for the treatment of AML should aim at eradicating LSCs. In addition, alternative strategies, targeting the bulk of blasts and causing significantly fewer side effects as compared with conventional chemotherapy, are desired. Consequently, the identification of targets on the cell surface of leukemic cells, in particular LSCs, has attracted much attention.^[@bib6]^ Among these, the CD33 and CD123 antigens are highly promising candidates for targeted therapy of AML.^[@bib6]^

High CD33 expression on AML blasts was already reported three decades ago.^[@bib7]^ CD33 was detected on blasts of 85--90% of patients presenting with AML as well as on normal myeloid progenitors and myelocytes.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^ Interestingly, CD33 seems to be restricted to hematopoietic cells,^[@bib12],\ [@bib13]^ but absent on normal hematopoietic stem cells,^[@bib14],\ [@bib15],\ [@bib16],\ [@bib17]^ making it an ideal target for AML therapy. In fact, the anti-CD33 immunoconjugate gemtuzumab ozogamicin (GO; Mylotarg) was granted accelerated approval in the United States following a phase II trial reporting a 30% response rate.^[@bib18],\ [@bib19]^ However, safety concerns and initial failure to demonstrate improved efficacy led to discontinuation of commercial availability of GO.^[@bib20],\ [@bib21]^ Observed side effects were most likely caused by a dissociation of calicheamicin from the anti-CD33 monoclonal antibody.^[@bib21]^ Subsequent clinical trials showed high efficacy of GO against acute promyelocytic leukemia (AML M3) and fractionated doses of GO in combination with chemotherapy yielded promising results in the treatment of other AML subtypes.^[@bib19],\ [@bib22],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26]^ Moreover, multidrug resistance mechanisms were frequently observed in response to GO treatment.^[@bib24],\ [@bib27]^ Development of resistance mechanisms was reported to be reduced in preclinical studies using the anti-CD33 immunotoxin SGN-CD33A.^[@bib28]^ Taken together, CD33 is a highly promising target in AML. Therapeutic strategies aiming at this antigen, however, need to be refined. Apart from alternative dosing regimens of GO, novel formats devoid of safety issues connected to immunotoxins, such as the recently developed bi-specific monoclonal antibodies, could increase therapeutic benefit while reducing side effects.^[@bib15],\ [@bib29],\ [@bib30]^

Incorporating additional antigens, which clearly separate normal and leukemic hematopoietic stem/progenitor cells into a combined approach, could further increase efficacy and specificity of antileukemic immunotherapy. In this regard, CD123 expression was observed on cells of the myeloid lineage and on AML blasts, as well as on LSCs in 75--89% of AML patients,^[@bib31],\ [@bib32],\ [@bib33]^ while being absent on normal hematopoietic stem cells.^[@bib32]^ These observations have led to the subsequent preclinical development of antibody-based targeting strategies for CD123.^[@bib34],\ [@bib35]^ CD123 expression seems to be rather specific to hematopoietic cells, although expression on subsets of endothelial cells has been reported.^[@bib36]^

Even though several studies have already addressed the expression of CD33 and CD123 individually in AML patient samples,^[@bib7],\ [@bib8],\ [@bib10],\ [@bib32],\ [@bib33],\ [@bib37]^ these cohorts have been rather small and restricted to subgroups with respect to French--American--British/World Health Organization (FAB/WHO) classification, cytogenetics, mutations and associated risk factors. Therefore, larger and more comprehensive studies additionally addressing the coexpression of CD33 and CD123 in AML patients are needed to set the stage for combinatorial immunotherapeutic approaches or novel trivalent constructs directing antileukemic immune effector cell activity to leukemic cells expressing these antigens.^[@bib29],\ [@bib38]^ Thus, we have analyzed the expression of CD33 in AML samples of 319 patients and CD123 alone and in combination with CD33 in AML samples of 298 of these patients by flow cytometry. In-depth analysis of CD33 and CD123 expression by AML subtypes and genetic characteristics revealed that both targets are widely expressed in AML subtypes and that their expression is equally high in patients with favorable, intermediate and poor prognosis, but particularly high in some high-risk patient groups, which are prime candidates for clinical trials.

Materials and methods
=====================

Patients
--------

Between May 2012 and June 2013, BM (305) or peripheral blood (14) from 319 newly diagnosed AML patients (median age 63 years; range 17--88), enrolled in the Study Alliance Leukemia AML registry, was immunophenotyped in our laboratory as part of the routine diagnostic procedure for leukemias.^[@bib39]^ These studies were approved by the ethical board of the Technische Universität Dresden. All patients gave written informed consent to participate.

Flow cytometric analysis of AML samples
---------------------------------------

The following antibodies from the indicated suppliers were used: BD Biosciences (San Jose, CA, USA)---CD34 (8G12), CD45 (HI30), CD33 (P67.6), CD117 (104D2) and HLA-DR (L243). BioLegend (San Diego, CA, USA)---CD123 (6H6). Samples were analyzed on a FACSCanto II cytometer (BD Biosciences). Measurements and analyses were performed using FACSDiva software (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR, USA). A total of 20 000 events per sample were recorded. Instrument setup including fluorescence amplification and compensation was fixed automatically applying FACSDiva compensation setup. Flow cytometer performance was checked regularly using CS&T beads (BD Biosciences). Leukemic blasts and lymphocytes were gated based on their CD45 expression and side scatter. The appropriate gate setting was verified by backgating CD34-, HLA-DR- and CD117-positive events, respectively. Blasts from AML patients were analyzed by flow cytometry ([Figure 1a](#fig1){ref-type="fig"}). The geometric mean fluorescence intensities (MFIs) of CD33 and CD123 of blasts were normalized to the MFIs of lymphocytes, which are negative for both surface markers. The resulting GeoMean ratios were applied to subsequent analyses, in which samples with a GeoMean ratio \>10 were considered positive, as this represents a log-shift in the fluorescence signal compared with the negative lymphocytes ([Figure 1b](#fig1){ref-type="fig"}). For comparison, MFI ratios of CD34^+^ CD45~dim~ SSC~low~ cells of 20 healthy BM donors relative to the MFI of their lymphocytes were determined.

Cytogenetic, molecular and morphologic analyses
-----------------------------------------------

Cytogenetic, molecular and morphologic analyses have been performed as described previously.^[@bib2],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42],\ [@bib43],\ [@bib44]^

Graphs and statistics
---------------------

Graphs were prepared and statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Two groups were compared with an unpaired two-tailed *t*-test. Multigroup comparisons were carried out with a one-way analysis of variance, followed by Tukey\'s multiple comparison test. Differences with a *P*-value of \<0.05 were considered statistically significant. In the case of multigroup comparisons, multiplicity-adjusted *P*-values were used and reported.

Results
=======

The majority of AMLs are positive for CD33 and CD123
----------------------------------------------------

In general, blast populations appeared homogenous with regard to the expression of CD33 and CD123. AML samples of 87.8% (280/319) were positive for CD33, whereas 77.9% (232/298) expressed CD123 ([Figures 2a and b](#fig2){ref-type="fig"}). Positivity for both markers was observed in 69.5% (207/298) of cases; 16.8% (50/298) of AML cases were CD33^+^/CD123^−^, whereas 9.4% (28/298) were CD33^−^/CD123^+^ ([Figure 2c](#fig2){ref-type="fig"}). The remaining 4.3% (13/298) neither expressed CD33 nor CD123. Thus, as also shown in the scatter plot in [Figure 2d](#fig2){ref-type="fig"}, CD33 and CD123 are very frequently expressed and often coexpressed on AML blasts. A significant correlation between CD33 and CD123 expression was observed according to Pearson\'s test (*r*=0.1846; *P*=0.0014).

Expression on AML blasts versus normal myeloid progenitors
----------------------------------------------------------

To compare the expression of CD33 and CD123 on normal myeloid progenitor cells with AML blasts, we therefore normalized the MFI ratios of CD34^+^ CD45~dim~ SSC~low~ cells of 20 healthy BM donors to the MFI of their lymphocytes. Interestingly, leukemic blasts expressed significantly higher levels of CD33 and CD123 compared with normal myeloid progenitors ([Figure 2e](#fig2){ref-type="fig"}).

Expression of CD33 and CD123 by FAB/WHO subtype
-----------------------------------------------

Next, expression of CD33 and CD123 by FAB/WHO subtypes was assessed. Hundred percent of M3 and M6 AMLs were highly positive for CD33 and CD123 ([Figures 3a and b](#fig3){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). High CD33 expression levels were observed in all AML subtypes (except for M7, *N*=1). FAB subtypes M2, M3, M4, M5 and M6 expressed the highest CD33 levels, whereas expression in M0, M1, M4~Eo~ and AML subtypes with myelodysplasia-related changes (AML-MRC) was somewhat lower ([Figure 3a](#fig3){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). When considering not the quantitative level of expression but the mere percentage of positive cases, the highest CD33 positivity of 92--100% was observed in M2, M3, M4, M4~Eo~ and M6, whereas only 81--85% of M0 and M1 and only around 70% of M5 and AML-MRC were CD33 positive ([Table 1](#tbl1){ref-type="table"}).

With regard to its levels, CD123 was highly expressed in M3, M4, M5 and M6, whereas M0, M1 and M4~Eo~ expressed somewhat lower levels ([Figure 3b](#fig3){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). M2 and AML-MRC had rather low CD123 levels and the only M7 sample was negative. A high percentage of CD123 positivity of 80--100% was observed in M0, M1, M3, M4, M4~Eo~, M5 and M6, whereas only around 60--67% of M2 and AML-MRC were CD123 positive ([Table 1](#tbl1){ref-type="table"}).

As M4 AMLs are characterized by the coexistance of a malignant monocytic population, we compared CD33 and CD123 expression in blast versus monocytic population in 23 M4 AML cases. Interestingly, the monocytic population had a significant 2.74-fold higher mean CD33 expression than the corresponding blast population, whereas there was no significant difference in CD123 expression ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Expression of CD33 and CD123 by cytogenetics and molecular alterations
----------------------------------------------------------------------

We further assessed the distribution of CD33 and CD123 expression based on the cytogenetic and molecular characteristics of the AML samples. Strikingly, we observed a significantly higher CD33 expression on AML blasts with FMS-related tyrosine kinase 3-internal tandem duplication (*FLT3*-ITD) mutations or nucleophosmin (*NPM1*) mutations compared with AML blasts without *FLT3*-ITD or *NPM1* alterations ([Figure 3c](#fig3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Moreover, blasts of patients with monosomy 5 showed significantly increased levels of CD33 ([Figure 3d](#fig3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). CD33 levels in t(15;17) blasts were nonsignificantly increased compared with negative cases, whereas t(8;21) leukemias had significantly lower CD33 expression compared with samples ([Figure 3c](#fig3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}).

Similarly, CD123 expression was significantly higher in AML blasts with *FLT3*-ITD mutations or *NPM1* mutations compared with AML blasts with wild-type (wt) *FLT3* or *NPM1*, whereas increased CD123 expression in t(15;17) samples and the lower CD123 expression in t(8;21) samples were not significant ([Figure 3e](#fig3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Although blasts of most patients with monosomy 5 were CD123 positive, its expression was not as high as in the case of CD33. Interestingly, a single sample with t(6;11) showed high levels of both CD33 and CD123.

Expression of CD33 and CD123 based on *FLT3* status
---------------------------------------------------

As blasts of patients with *FLT3* mutations expressed significantly higher CD33 and CD123 protein on their cell surface than those with *FLT3* wt, we dissected CD33 and CD123 expression with regard to *FLT3* mutational status in greater detail. While the presence of an *FLT3*-ITD mutation *per se* is a marker for unfavorable prognosis,^[@bib45]^ it was previously reported that, especially, a ratio of mutated *FLT3* to *FLT3* wt of \>0.78 predicts poor outcome.^[@bib42]^ Thus, we compared CD33 and CD123 expression in AMLs without *FLT3*-ITD, a mutant (mut)/wt ratio \<0.78 and a ratio \>0.78. Interestingly, CD33 and CD123 expression increased from wt (median 26, range 1--164) to low mut/wt ratio (median 55, range 2--103) and further to a high mut/wt ratio (median 69, range 15--148; [Figure 4a](#fig4){ref-type="fig"}). Likewise, CD123 expression increased from wt (median 16, range 2--95) to low mut/wt ratio (median 30, range 8--195) further to a high mut/wt ratio (median 46, range 11--148; [Figure 4b](#fig4){ref-type="fig"}). Because of these striking results, we analyzed additional 11 patient samples with *FLT3* mut/wt ratios \>0.78 from the Study Alliance Leukemia AML registry. These measurements uniformly confirmed the high CD33 and CD123 expression levels in this group ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

Expression of CD33 and CD123 based on the combined *FLT3*-ITD and *NPM1* status
-------------------------------------------------------------------------------

It has been reported that patients with *NPM1* mutation but no *FLT3*-ITD have a favorable prognosis.^[@bib41]^ Thus, we compared CD33 and CD123 blast cell surface expression in this group with the other groups of patients. Patients with *NPM1* mutation, irrespective of their *FLT3*-ITD status, had significantly higher levels of CD33 (median 59, range 10--164) than *NPM1* wt/*FLT3*-ITD− patients (median 26, range 1--145; *P*-value *t*-test 2.96E−10; [Supplementary Figure 3A](#sup1){ref-type="supplementary-material"}). Similarly, CD123 levels were significantly higher in patients with *NPM1* mutation (median 30, range 9--195) as compared with *NPM1* wt/*FLT3*-ITD− patients (median 15, range 2--69; *P*-value *t*-test 3.84E−10; [Supplementary Figure 3B](#sup1){ref-type="supplementary-material"}).

CD33 and CD123 expression by risk group
---------------------------------------

All 236 patients with sufficient genetic information were classified into risk groups based on cytogenetic and mutation analyses according to a recommendation by the European LeukemiaNet^[@bib46]^ with the modification that patients with an *FLT3* mut/wt ratio \>0.78 were added to the poor prognosis group^[@bib42]^ ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). No significant differences were seen between the three risk groups with regard to their CD33 and CD123 levels ([Figure 4c and d](#fig4){ref-type="fig"}).

Expression of CD33 and CD123 in the CD34^+^ blast population only
-----------------------------------------------------------------

As LSCs are contained in the CD34^+^CD38^−^ or CD34^+^CD38^+^ blast population in the vast majority of AML cases,^[@bib47],\ [@bib48],\ [@bib49],\ [@bib50]^ we determined the expression of CD33 and CD123 in the CD34^+^ blast population of CD34^+^ leukemias as described above for overall blasts. CD34^+^ populations of 88.6% (249/281) of AML samples were positive for CD33, whereas 80.7% (213/264) expressed CD123 ([Figures 5a and b](#fig5){ref-type="fig"}). Positivity for both markers was observed in 73.1% (193/264) of cases, 15.5% (41/264) were CD33^+^/CD123^−^, whereas 7.6% (20/264) were CD33^−^/CD123^+^ ([Figure 5c](#fig5){ref-type="fig"}). The remaining 3.8% (10/264) neither expressed CD33 nor CD123. Thus, the blast compartment that contains LSCs expressed CD33 and/or CD123 in most AML cases.

Discussion
==========

We have analyzed the cell surface expression of CD33 and CD123 in AML blasts in a highly comprehensive manner and a larger data set compared with previous studies. We observed the expression of both markers in the vast majority of AML cases in the total blast population and in the CD34^+^ fraction of CD34^+^ AML, which is presumed to contain the LSCs in most patients.^[@bib47],\ [@bib48],\ [@bib49]^ CD33 and CD123 showed a higher expression on AML blasts than on myeloid progenitors of healthy donors. The highest percentages of CD33 positivity and the highest expression levels were observed in M2, M3, M4, M5 and M6. The distribution of CD123 expression among the FAB/WHO groups was very similar to that of CD33, with the difference that CD123 expression (% and level) was lower in the M2 group. Hundred percent of M3 and M6 leukemias were CD33^+^ and CD123^+^. The fact that all M3 AMLs are CD33^+^ has previously been reported.^[@bib11],\ [@bib51]^ Interestingly, we observed high expression of CD33 in patients with *FLT3* mut/wt ratios \>0.78 and in patients with monosomy 5, with all of them being CD33^+^, arguing that these patients, who have a poor prognosis when treated with conventional therapy, might benefit from CD33-targeted therapies. Both groups also expressed high levels of CD123. When grouping all patients according to their prognostic outcome, no significant difference in CD33 or CD123 expression was observed between the three risk groups, suggesting that generally poor prognosis patients might profit to the same extent from targeted therapies against CD33 and CD123. While monotargeting against either CD33 or CD123 should be effective against most AML blasts and LSCs, as only around 4% of AMLs were negative for both markers, dual targeting against CD33^+^CD123^+^ double-positive cells would increase specificity and binding affinity in around 70% of cases. Our data would predict that the vast majority of patients with M3, M4, M5 and M6 leukemias would benefit from such therapies, as well as nearly all patients with *FLT3*-ITD and *NPM1* mutations (see also [Supplementary Figure](#sup1){ref-type="supplementary-material"}), whereas M4~Eo~ patients would benefit least from dual-targeting strategies. Such strategies can either be designed to kill only double-positive cells or to eliminate any single- and double-positive cells.^[@bib52]^ If well tolerated, the latter strategy should be effective against 96% of AMLs. Clinical trials with GO reported high efficacy in low-risk AMLs, but not high-risk disease, which is likely explained by the preferential development of resistance mechanisms in high-risk AMLs.^[@bib24],\ [@bib27]^ Such evasion mechanisms are unlikely to occur when T cells are retargeted to leukemic cells using bi-specific antibodies. Therefore, such antibodies targeting CD33 should be more effective against high-risk leukemias as compared with GO. Moreover, targeting AMLs via cell surface proteins should be superior to targeting deregulated signaling pathways, considering the multiclonal nature of AMLs.^[@bib53],\ [@bib54]^

Of note, the definition used here for CD33 positivity of an AML sample differs from the one used in the clinic, which defines a CD33^+^ AML by the presence of at least 20--25% CD33^+^ blasts.^[@bib7],\ [@bib8]^ As the aim of this study was to quantify cell surface expression with the perspective of specific targeting, the mean expression value of the blast population is much more meaningful then the percentage of positive cells above a certain threshold. Along these lines, a recent report has described the immunophenotypic pattern of normal and malignant myeloid cells.^[@bib11]^ However, the CD33 expression data was presented in a non-quantitative manner. Likewise, a previous study has addressed the expression of CD123 in 45 AML samples and reported its expression in all FAB subtypes, except for two cases of M7 megakaryoblastic leukemia.^[@bib33]^ Consistently, we also observed the absence of CD123 in a single M7 sample. In contrast to our data, the corresponding data were analyzed and presented in a non-quantitative manner, which does not allow any conclusion with regard to CD123 expression levels.

In accordance with a previous report,^[@bib55]^ we observed low CD33 expression levels in blasts of patients with t(8;21). Another recent study reported higher CD33 expression in AMLs with *NPM1* mutation,^[@bib56]^ which is confirmed by our findings. However, in the same study, no correlation between *FLT3* mutations and CD33 expression was observed, which is in contrast to our results. This might be explained by the larger cohort evaluated in our study. Interestingly, Pollard *et al.*^[@bib57]^ recently reported that high CD33 expression correlates with the presence of *FLT3*-ITD mutations in childhood AMLs. Similarly, higher CD123 expression in *FLT3*-ITD AMLs compared with *FLT3* wt AMLs was reported previously based on flow cytometry data.^[@bib58],\ [@bib59]^ Moreover, a immunohistochemical study of CD123 expression reported correlations of CD123 expression with *FLT3*-ITD and *NPM1* mutations, which is consistent with our data.^[@bib60]^ Surprisingly, only 40% of AMLs were CD123^+^ in this study, which may be explained by the different method used to assess CD123 expression.

Highly promising results are achieved by treating chemotherapy--refractory minimal residual disease in B-cell acute lymphoblastic leukemia with the bi-specific CD3--CD19 antibody blinatumomab.^[@bib61]^ Similarly, efficacy of bi-specific antibodies targeting AMLs via CD33 or CD123 should be assessed in patients with minimal residual disease after induction therapy. We have recently reported that *NPM1* mut is suitable for detection of minimal residual disease and to be predictive of poor prognosis after relapse.^[@bib40]^ As we have observed significantly higher CD33 and CD123 expression in AMLs with *NPM1* mut as compared with those with *NPM1* wt, we propose that first clinical trials should include AML patients with minimal residual disease based on positivity for *NPM1* mut. Interestingly, previous studies reported the persistence of CD33 expression after relapse in CD33^+^ AML^[@bib62],\ [@bib63]^ and one study even reported that 45% of CD33^−^ AML gained CD33 at relapse,^[@bib63]^ arguing that CD33 may be an ideal target for second-line treatment, as its expression persists and might even be enhanced after chemotherapy.

Anti-CD33 therapy should efficiently target the bulk of blasts with potentially fewer side effects as compared with conventional chemotherapy. It has been debated whether or not LSCs express CD33.^[@bib25]^ Our data on CD33 expression in the CD34^+^ population of CD34^+^ leukemias are in line with several studies, which conclude that LSCs of many AMLs express CD33 and would therefore be eradicated by anti-CD33 therapy.^[@bib17],\ [@bib25],\ [@bib37]^ Likewise, our data suggest that CD123 would efficiently target blasts as well as LSCs, which is in accordance with previous reports.^[@bib32],\ [@bib33]^

In conclusion, our results suggest that tailored immunotherapies targeting CD33 and CD123 are likely to enhance treatment efficacy in the majority of AML patients.
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![Gating scheme of flow cytrometric analysis of CD33 and CD123 expression in AML blasts. (**a**) After excluding doublets and debris, lymphocytes and blasts were selected based on their SSC and CD45 expression profiles. If present, CD34 expression was used to further characterize the blast population. Thereafter, CD33 and CD123 expression was analyzed. (**b**) The geometric mean fluorescence intensities (MFIs) of CD33 and CD123 on blasts were normalized to the MFI of lymphocytes, which are negative for both surface markers. GeoMean ratios of 5, 10, 25, 50 and 100 are displayed in the graph together with representative FACS plots. FCS, forward scatter; SSC, side scatter.](bcj201439f1){#fig1}

![The majority of AMLs are positive for CD33 and CD123. (**a**) Pie chart showing distribution of CD33 positivity among 319 samples analyzed (GeoMean ratio blasts/lymphocytes ⩾10 was considered positive). (**b**) Pie chart depicting distribution of CD123 positivity among 298 samples analyzed. (**c**) Pie chart showing distribution of CD33 and CD123 positivity among 298 samples analyzed. (**d**) Scatter plot depicting distribution of CD33 and CD123 expression (GeoMean ratios blasts/lymphocytes) among 298 samples analyzed. (**e**) Box plots showing CD33 and CD123 expression by normal myeloid progenitors and AML blasts. *P*-values are based on unpaired two-tailed *t*-test.](bcj201439f2){#fig2}

![Expression of CD33 and CD123 by FAB/WHO subtype, cytogenetics and mutations. Box plots showing distribution of CD33 expression (**a**) or CD123 expression by FAB/WHO subtype (**b**). For further details see also [Table 1](#tbl1){ref-type="table"}. Box plots visualizing distribution of CD33 expression (**c** and **d**) or CD123 expression (**e** and **f**) based on cytogenetic features and common mutations. *P*-values are based on unpaired two-tailed *t*-test. For further details see also [Table 2](#tbl2){ref-type="table"}.](bcj201439f3){#fig3}

![Expression of CD33 and CD123 by risk group. Box plots showing expression of CD33 (**a**) and CD123 (**b**) based on *FLT3* status (*FLT3* wt, a mutant/wild-type ratio \<0.78 and a ratio \>0.78). Box plots depicting expression of CD33 (**c**) and CD123 (**d**) in AML blasts grouped by prognosis. *P*-values are based on one-way analysis of variance followed by Tukey\'s multiple comparison test.](bcj201439f4){#fig4}

![The majority of CD34^+^ AMLs express CD33 and CD123 in their CD34^+^ blast population. (**a**) Pie chart showing expression of CD33 in the CD34^+^ blast population of CD34^+^ leukemias (samples with a GeoMean ratio CD34^+^ blasts/lymphocytes ⩾10 were considered positive). (**b**) Pie chart depicting expression of CD123 in the CD34^+^ blast population of CD34^+^ leukemias. (**c**) Pie chart visualizing expression of CD33 and CD123 in the CD34^+^ blast population of CD34^+^ leukemias.](bcj201439f5){#fig5}

###### Expression of CD33 and CD123 by FAB/WHO subtype

  *FAB/WHO subtype*   *Mean*[a](#t1-fn1){ref-type="fn"} *CD33 expression*   *S.d.*   N    *% Positive (GeoMean ratio \>10)*
  ------------------- ----------------------------------------------------- -------- ---- -----------------------------------
  *CD33*                                                                                  
   M0                 29.5                                                  26.9     21   81.0
   M1                 35.1                                                  27.5     53   84.9
   M2                 44.5                                                  36.5     50   96.0
   M3                 62.4                                                  29.3     12   100.0
   M4                 47.3                                                  31.7     46   97.8
   M4Eo               25.9                                                  13.4     12   91.7
   M5                 47.0                                                  45.5     23   73.9
   M6                 82.0                                                  28.3     2    100.0
   M7                 3.0                                                   NA       1    0.0
   AML-MRC            29.5                                                  26.7     13   69.2
  *CD123*                                                                                 
   M0                 23.4                                                  17.3     20   80.0
   M1                 22.4                                                  15.6     50   84.0
   M2                 15.4                                                  11.6     30   60.0
   M3                 33.3                                                  13.6     9    100.0
   M4                 30.8                                                  27.9     41   87.8
   M4Eo               21.5                                                  20.9     10   90.0
   M5                 40.4                                                  47.9     21   85.7
   M6                 31.5                                                  17.7     2    100.0
   M7                 7.0                                                   NA       1    0.0
   AML-MRC            19.7                                                  24.2     12   66.7

Abbreviations: AML, acute myeloid leukemia; FAB, French--American--British; MRC, myelodysplasia-related changes; NA, not available; WHO, World Health Organization.

Arithmetic mean of GeoMean ratios.

###### CD33 and CD123 expression by cytogenetics and molecular alterations

  *Cytogenetics/mutation*   *Mean*[a](#t2-fn1){ref-type="fn"} *CD33 expression*   *S.d.*   N     *% Positive (GeoMean ratio \>10)*    P*-value unpaired two-tailed* t*-test*
  ------------------------- ----------------------------------------------------- -------- ----- ----------------------------------- ----------------------------------------
  *CD33*                                                                                                                             
   FLT3 wt                  38.5                                                  31.9     219   88.1                                                    
   FLT3 mut                 55.0                                                  35.6     58    93.1                                              **7.19E−04**
   NPM1 wt                  33.9                                                  27.7     190   85.3                                                    
   NPM1 mut                 63.3                                                  37.4     62    100.0                                             **2.87E−10**
   CEBPA wt                 42.0                                                  32.8     220   90.0                                                    
   CEBPA mut                32.1                                                  16.1     14    92.9                                                  0.26
   t(15;17) neg             40.7                                                  33.1     234   88.0                                                    
   t(15;17) pos             54.4                                                  24.8     10    100.0                                                 0.20
   t(8;21) neg              41.8                                                  32.8     242   88.8                                                    
   t(8;21) pos              16.2                                                  9.2      11    90.9                                                **0.01**
   inv(16) neg              41.3                                                  33.1     241   88.8                                                    
   inv(16) pos              27.1                                                  14.4     12    91.7                                                  0.14
   Monosomy 5 neg           40.0                                                  32.3     247   88.7                                                    
   Monosomy 5 pos           73.0                                                  35.1     5     100.0                                               **0.03**
   del(5q) neg              41.1                                                  33.1     235   88.9                                                    
   del(5q) pos              33.7                                                  25.4     18    88.9                                                  0.35
   Monosomy 7 neg           40.7                                                  32.5     238   89.1                                                    
   Monosomy 7 pos           40.4                                                  35.8     14    85.7                                                  0.97
   inv(3q) neg              40.8                                                  32.7     250   89.2                                                    
   inv(3q) pos              26.5                                                  30.4     2     50.0                                                   NA
   t(3;3) neg               40.2                                                  31.8     246   89.0                                                    
   t(3;3) pos               61.0                                                  58.7     6     83.3                                                  0.12
   t(6;9) neg               40.6                                                  32.8     250   88.8                                                    
   t(6;9) pos               47.0                                                  8.5      2     100.0                                                  NA
   t(6;11) neg              40.7                                                  32.7     251   88.8                                                    
   t(6;11) pos              41.0                                                  NA       1     100.0                                                  NA
  *CD123*                                                                                                                            
   FLT3 wt                  19.8                                                  14.4     208   76.9                                                    
   FLT3 mut                 44.8                                                  39.2     53    98.1                                              **1.31E−12**
   NPM1 wt                  20.6                                                  17.2     179   76.0                                                    
   NPM1 mut                 40.6                                                  36.3     56    94.6                                              **4.74E−08**
   CEBPA wt                 26.3                                                  26.0     205   79.0                                                    
   CEBPA mut                16.4                                                  6.4      14    100.0                                                 0.15
   t(15;17) neg             25.3                                                  25.1     221   80.1                                                    
   t(15;17) pos             33.3                                                  13.6     9     100.0                                                 0.34
   t(8;21) neg              25.8                                                  24.9     228   82.9                                                    
   t(8;21) pos              13.5                                                  11.3     11    36.4                                                  0.11
   inv(16) neg              25.4                                                  24.8     227   80.2                                                    
   inv(16) pos              21.4                                                  18.8     12    91.7                                                  0.58
   Monosomy 5 neg           25.4                                                  24.7     232   80.6                                                    
   Monosomy 5 pos           21.4                                                  17.5     5     80.0                                                  0.72
   del(5q) neg              25.5                                                  25.2     221   80.1                                                    
   del(5q) pos              21.3                                                  13.4     18    83.3                                                  0.48
   Monosomy 7 neg           25.3                                                  24.8     224   80.4                                                    
   Monosomy 7 pos           24.2                                                  20.5     13    84.6                                                  0.88
   inv(3q) neg              25.4                                                  24.6     235   80.9                                                    
   inv(3q) pos              7.5                                                   4.9      2     50.0                                                   NA
   t(3;3) neg               25.6                                                  24.8     231   81.0                                                    
   t(3;3) pos               14.0                                                  7.2      6     66.7                                                  0.26
   t(6;9) neg               25.4                                                  24.6     235   80.9                                                    
   t(6;9) pos               13.5                                                  14.8     2     50.0                                                   NA
   t(6;11) neg              25.2                                                  24.6     236   80.5                                                    
   t(6;11) pos              42.0                                                  NA       1     100.0                                                  NA

Abbreviations: CEBPA, CCAAT/enhancer-binding protein-α FLT3, FMS-related tyrosine kinase 3; mut, mutant; ITD, internal tandem duplication; NA, not available; neg, negative; NPM1, nucleophosmin; pos, positive; wt, wild type. Bold entries are statistically significant.

Arithmetic mean of GeoMean ratios.

[^1]: Members of the Study Alliance Leukemia registry are listed before references.
